Dr Therese Mooney is the Head of the Programme Evaluation Unit of the National Screening Service, Ireland. She has a PhD in Chemistry and MSc in Epidemiology from the London School of Hygiene and Tropical Medicine. She has been working in screening evaluation and research for over 20 years.

Dr. Bulliard is a trained epidemiologist (PhD), scientific Director of the Neuchâtel-Jura Swiss cancer registry, and a senior research and teaching fellow at the Centre for Primary Care and Public Health (Unisanté), University of Lausanne, where he leads the Sector Epidemiology and Public Health Data Science. Involved in cancer epidemiology and prevention for over 25 years, his expertise includes evaluation, modelling and implementation of cancer screening programmes (breast, colon and lung). Dr Bulliard has been actively involved within the ICSN since 1999, with participation to several ICSN scientific publications and working groups, and former member of its steering Committee.

1. Group leader on Early Detection of Cancer. The group focuses on the implementation and dissemination research on population-based cancer screening programs as well as the evaluation of new strategies on early detection of cancer. Research lines: Health impact assessment of cancer screening programs: studies on adverse effects and mortality reduction; Design & implementation of interventions aimed at improving screening programs; Decision-making in cancer screening 2. Quality Assurance Manager at the ICO screening hub for breast and colorectal cancer (Catalonia, Spain) to assist with the coordination and implementation of quality assurance activites.

Partha Basu, MD, PhD, FRCOG (Hon), is the Head of the Early Detection, Prevention, and Infection Branch at the IARC. He is a gynecologic-oncologist and globally recognized leader in cancer research and program implementation, with a focus on prevention. Recently, he has led several policy-relevant studies on the performance of cancer screening programs in Europe and globally, the evaluation of novel screening and treatment methods for cervical pre-cancers, and the assessment of HPV vaccination efficacy using reduced dose schedules.

Development manager at Finnish Cancer Registry, focusing on development of data collection and reporting, especially on colorectal cancer screening programme. As a researcher building statistical models for real-world scenarios where data is unobserved, misclassified and observed in time -- that is cancer screening.

She has a degree in Mathematics, a PhD in Public Health, and a Masters degree in Health Service Management. She has worked as a researcher at the Basque Health Service – Osakidetza, and has authored around 60 scientific papers. She developed her scientific career in the domain of health economics. Her principal expertise is the application of mathematical modelling in the epidemiological and economic evaluation of population-level interventions such as cancer screening.

Dr. Arlinda Ruco is an Assistant Professor at St. Francis Xavier University and a public health scientist and health services researcher with interests in cancer screening and prevention. Dr. Ruco's research program focuses on the development, implementation and evaluation of interventions for encouraging participation in cancer screening and on barriers and enablers of underscreened populations.